Ultimovacs ASA (OSL:ULTI) Change In Receivables : kr0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Change In Receivables?

Ultimovacs ASA's change in receivables for the quarter that ended in Dec. 2023 was kr0.00 Mil. It means Ultimovacs ASA's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Ultimovacs ASA's change in receivables for the fiscal year that ended in Dec. 2023 was kr0.00 Mil. It means Ultimovacs ASA's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Ultimovacs ASA's Accounts Receivable for the quarter that ended in Dec. 2023 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ultimovacs ASA's liquidation value for the three months ended in Dec. 2023 was kr196.91 Mil.

Ultimovacs ASA Change In Receivables Historical Data

The historical data trend for Ultimovacs ASA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Change In Receivables Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Ultimovacs ASA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Ultimovacs ASA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Ultimovacs ASA (OSL:ULTI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ultimovacs ASA's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Ultimovacs ASA's accounts receivable are only considered to be worth 75% of book value:

Ultimovacs ASA's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	266.559	-	69.647	+	0.75 * 0	+	0.5 * 0
=	196.91

Ultimovacs ASA Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.